Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocytes

被引:120
|
作者
Rabesandratana, H
Toutant, JP
Reggio, H
Vidal, M
机构
[1] Univ Montpellier 2, UMR 5539, F-34095 Montpellier, France
[2] Hop St Eloi, Cent Hematol Lab, Montpellier, France
[3] INRA, F-34060 Montpellier, France
关键词
D O I
10.1182/blood.V91.7.2573.2573_2573_2580
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Exosomes are membrane vesicles released by reticulocytes during their maturation into erythrocytes. They have a clearing function because of their enrichment with some proteins known to decrease or disappear from the cell surface during maturation, eg, acetylcholinesterase (AChE) and transferrin receptor (TIR), respectively. To better understand the molecular events leading to protein sorting in exosomes, we analyzed the expression of glycosylphosphatidylinositol (GPI)-anchored proteins on the exosome surface through a technique involving bead coupling and flow cytometry immunodetection. The presence of AChE, decay-accelerating factor (DAF), membrane inhibitor of reactive lysis (MIRL), and lymphocyte function-associated antigen 3 (LFA-3) on the surface of exosomes obtained from normal and paroxysmal nocturnal hemoglobinuria (PNH) reticulocytes, suggests that (1) the GPI anchor is efficiently sorted during exosome formation, (2) exosome release could account for the observed discrepancy in GPI-protein expression between reticulocytes and erythrocytes from PNH patients, and (3) exosomes could have another physiologic function related to controlling membrane attack complex formation. (C) 1998 by The American Society of Hematology.
引用
收藏
页码:2573 / 2580
页数:8
相关论文
共 50 条
  • [31] Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55)
    Hinchliffe, SJ
    Spiller, OB
    Rushmere, NK
    Morgan, BP
    JOURNAL OF IMMUNOLOGY, 1998, 161 (10): : 5695 - 5703
  • [32] Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo
    Loberg, Robert D.
    Day, LaShon L.
    Dunn, Rodney
    Kalikin, Linda M.
    Pienta, Kenneth J.
    NEOPLASIA, 2006, 8 (01): : 69 - 78
  • [33] Improving decay-accelerating factor (DAF, CD55) by substituting a GPI-anchor with a membrane-targeting address
    White, J
    Giddings, N
    Esser, D
    Thurston, K
    Steward, M
    Bright, JR
    Morgan, BP
    Smith, GP
    Smith, RAG
    MOLECULAR IMMUNOLOGY, 2001, 38 (2-3) : 128 - 128
  • [34] Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor
    Zhou, CY
    McInnes, E
    Copeman, L
    Langford, G
    Parsons, N
    Lancaster, R
    Richards, A
    Carrington, C
    Thompson, S
    XENOTRANSPLANTATION, 2005, 12 (02) : 142 - 148
  • [35] DETECTION OF THE MEMBRANE INHIBITOR OF REACTIVE LYSIS (CD59) IN DISEASED NEURONS OF ALZHEIMER BRAIN
    MCGEER, PL
    WALKER, DG
    AKIYAMA, H
    KAWAMATA, T
    GUAN, AL
    PARKER, CJ
    OKADA, N
    MCGEER, EG
    BRAIN RESEARCH, 1991, 544 (02) : 315 - 319
  • [36] Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
    Geis, N.
    Zell, S.
    Rutz, R.
    Li, W.
    Giese, T.
    Mamidi, S.
    Schultz, S.
    Kirschfink, M.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 922 - 931
  • [37] Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/Ipr mice
    Miwa, T
    Maldonado, MA
    Zhou, L
    Sun, XJ
    Luo, HY
    Cai, DW
    Werth, VP
    Madaio, MP
    Eisenberg, RA
    Song, WC
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (03): : 1077 - 1086
  • [38] RELATIVE ROLES OF DECAY-ACCELERATING FACTOR, MEMBRANE COFACTOR PROTEIN, AND CD59 IN THE PROTECTION OF HUMAN ENDOTHELIAL-CELLS AGAINST COMPLEMENT-MEDIATED LYSIS
    BROOIMANS, RA
    VANWIERINGEN, PAM
    VANES, LA
    DAHA, MR
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (12) : 3135 - 3140
  • [39] Effect of immunosuppressive drugs on the decay-accelerating factor (CD55); implications for a subset of myasthenia gravis patients
    Abrahams, A.
    Auret, J.
    Prince, S.
    Heckmann, J. M.
    FEBS JOURNAL, 2011, 278 : 322 - 322
  • [40] Structural basis for CD97 recognition of the decay-accelerating factor CD55 suggests mechanosensitive activation of adhesion GPCRs
    Niu, Minghui
    Xu, Shengzhao
    Yang, Jie
    Yao, Deqiang
    Li, Na
    Yan, Jie
    Zhong, Guisheng
    Song, Gaojie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 296